18:25 , Jun 13, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other Exosomes could be used to deliver peptide-conjugated nucleic acid therapies for multiple diseases. The method involves loading exosomes with therapeutic nucleic acids conjugated to a 12-amino acid peptide engineered to bind the extracellular...
19:10 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Bringing home exosomes

Researchers at the University of California San Diego published the first proof-of-concept data showing Biological Dynamics Inc. 's exosome-on-a-chip platform can isolate the extracellular vesicles and their proteins in under 30 minutes, without damaging them....
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Rhizen, TG Therapeutics preclinical data

In vitro, TGR-1202 inhibited B cell proliferation and induced CD63 expression. Additionally, TGR-1202 inhibited cell growth and induced apoptosis in MM cell lines. Data were presented at the European Hematology Association meeting in Stockholm. TG...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Company News

Arius, Roche deal

Roche will acquire antibody platform company Arius for about C$191 million (US$190.7 million) in cash. The deal includes the purchase of Arius’ common shares at C$2.44 and the purchase of issued and outstanding warrants at...
07:00 , Mar 20, 2008 |  BC Innovations  |  Targets & Mechanisms

CF: New Roles for Neutrophils

Although cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator channel, disease progression is thought to stem primarily from pulmonary damage caused by elastase . The prevailing theory is that...
08:00 , Feb 4, 2008 |  BioCentury  |  Product Development

Arius picks its epitope

Even though the last antibody targeting CD44 to enter the clinic was dropped because of toxicity, Arius Research Inc. , which plans to submit an IND for huARH460-16-2 (AR001) this year, is not concerned. The...